S

Sandoz Group AG
SIX:SDZ

Watchlist Manager
Sandoz Group AG
SIX:SDZ
Watchlist
Price: 62.96 CHF 1.22% Market Closed
Market Cap: CHf27.7B

Net Margin

2.7%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
2.7%
=
Net Income
$227m
/
Revenue
$10.6B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
2.7%
=
Net Income
CHf227m
/
Revenue
$10.6B

Peer Comparison

Country Company Market Cap Net
Margin
CH
Sandoz Group AG
SIX:SDZ
26.8B CHF
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
F:1PK
5.1B EUR
Loading...
US
Johnson & Johnson
NYSE:JNJ
528.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
CH
Novartis AG
SIX:NOVN
221.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
267.9B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.6B USD
Loading...

Market Distribution

In line with most companies in Switzerland
Percentile
35th
Based on 1 179 companies
35th percentile
2.7%
Low
-57 027.8% — 1.3%
Typical Range
1.3% — 13.7%
High
13.7% — 3 663.7%
Distribution Statistics
Switzerland
Min -57 027.8%
30th Percentile 1.3%
Median 7.2%
70th Percentile 13.7%
Max 3 663.7%

Sandoz Group AG
Glance View

Market Cap
27.7B CHF
Industry
Pharmaceuticals

Sandoz Group AG, a renowned player in the pharmaceutical industry, stands as a global leader in the production of generic drugs and biosimilars. Originally part of the Swiss corporate giant Novartis, Sandoz has cultivated a reputation for delivering affordable healthcare solutions across the globe. Its foundation lies in the manufacturing of cost-effective, high-quality alternatives to branded medicines, making healthcare more accessible to a broader public. By focusing on generic pharmaceuticals—drugs that are comparable to branded products in terms of dosage, safety, strength, quality, and performance—Sandoz effectively manages to carve out a vital niche in the healthcare ecosystem. This strategic emphasis allows the company to offer a vast portfolio that spans across major therapeutic areas such as cardiovascular, central nervous system, pain management, and oncology, to name a few. Sandoz's business model hinges on its ability to streamline production processes and efficiently navigate regulatory landscapes, which enables the company to sell its products at competitive prices while maintaining profitability. One critical aspect of their operation is the capability to innovate within the generic space, exemplified by their expansion into biosimilars—biopharmaceutical drugs that are highly akin to existing biological products. As patents for major biologics expire, Sandoz capitalizes on the opportunity to introduce biosimilars, thus broadening access to complex therapies. The company invests significantly in research and development to enhance its pipeline of generic drugs and biosimilars, ensuring a steady flow of new market entries. Through a combination of strategic pricing, diverse product offerings, and robust R&D efforts, Sandoz sustains its business model while contributing profoundly to global health, embodying a mission of "Pioneering Access for Patients."

SDZ Intrinsic Value
56.99 CHF
Overvaluation 9%
Intrinsic Value
Price
S
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
2.7%
=
Net Income
$227m
/
Revenue
$10.6B
What is Sandoz Group AG's current Net Margin?

The current Net Margin for Sandoz Group AG is 2.7%, which is in line with its 3-year median of 2.7%.

How has Net Margin changed over time?

Over the last 0 months, Sandoz Group AG’s Net Margin has increased from 2.7% to 2.7%. During this period, it reached a low of 2.7% on Jul 30, 2025 and a high of 2.7% on Jul 30, 2025.

Back to Top